留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肾移植相关血栓性微血管病的诊断及治疗进展

李大伟, 张明. 肾移植相关血栓性微血管病的诊断及治疗进展[J]. 器官移植, 2023, 14(1): 68-74. doi: 10.3969/j.issn.1674-7445.2023.01.009
引用本文: 李大伟, 张明. 肾移植相关血栓性微血管病的诊断及治疗进展[J]. 器官移植, 2023, 14(1): 68-74. doi: 10.3969/j.issn.1674-7445.2023.01.009
Li Dawei, Zhang Ming. Progress on diagnosis and treatment of kidney transplantation-associated thrombotic microangiopathy[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 68-74. doi: 10.3969/j.issn.1674-7445.2023.01.009
Citation: Li Dawei, Zhang Ming. Progress on diagnosis and treatment of kidney transplantation-associated thrombotic microangiopathy[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 68-74. doi: 10.3969/j.issn.1674-7445.2023.01.009

肾移植相关血栓性微血管病的诊断及治疗进展

doi: 10.3969/j.issn.1674-7445.2023.01.009
基金项目: 

国家自然科学基金 81800657

中国器官移植发展基金会器官移植专项扶持“菁英计划” 2019JYJH14

详细信息
    作者简介:
    通讯作者:

    张明, Email: drmingzhang@126.com

  • 中图分类号: R617, R543

Progress on diagnosis and treatment of kidney transplantation-associated thrombotic microangiopathy

More Information
  • 摘要: 血栓性微血管病(TMA)是肾移植术后较为严重的并发症,以血小板减少、微血管溶血性贫血和急性肾损伤为主要特征,可导致移植肾失功甚至受者死亡。随着我国实体器官移植数量的不断增加,以及对TMA认识的提高,其相关研究也在逐步深入。肾移植相关TMA病因多样,临床表现各异,缺乏特异性的无创检测手段。多数TMA的确诊依赖于肾穿刺活组织检查,但由于TMA多伴随有血小板明显降低,肾穿刺风险较大,明确诊断存在一定困难。针对肾移植相关TMA,目前通常使用血浆置换、静脉注射免疫球蛋白以及停用潜在风险药物等综合治疗方式,但总体预后不佳。本文现就肾移植术后TMA的分类、肾移植相关TMA的诊断及治疗做一综述,以期为临床肾移植相关TMA的诊断和治疗提供参考。

     

  • [1] VAN HERPT TTW, TIMMERMANS SAMEG, VAN MOOK WNKA, et al. Postsurgical thrombotic microangiopathy and deregulated complement[J]. J Clin Med, 2022, 11(9): 2501. DOI: 10.3390/jcm11092501.
    [2] ABOU-ISMAIL MY, KAPOOR S, CITLA SRIDHAR D, et al. Thrombotic microangiopathies: an illustrated review[J]. Res Pract Thromb Haemost, 2022, 6(3): e12708. DOI: 10.1002/rth2.12708.
    [3] ÁVILA A, GAVELA E, SANCHO A. Thrombotic microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity[J]. Front Med (Lausanne), 2021, 8: 642864. DOI: 10.3389/fmed.2021.642864.
    [4] BROCKLEBANK V, WOOD KM, KAVANAGH D. Thrombotic microangiopathy and the kidney[J]. Clin J Am Soc Nephrol, 2018, 13(2): 300-317. DOI: 10.2215/CJN.00620117.
    [5] VANIKAR AV, KANODIA KV, SUTHAR KS, et al. Thrombotic microangiopathy in a renal allograft: single-center five-year experience[J]. Saudi J Kidney Dis Transpl, 2020, 31(6): 1331-1343. DOI: 10.4103/1319-2442.308342.
    [6] SAIKUMAR DORADLA LP, LAL H, KAUL A, et al. Clinical profile and outcomes of de novo posttransplant thrombotic microangiopathy[J]. Saudi J Kidney Dis Transpl, 2020, 31(1): 160-168. DOI: 10.4103/1319-2442.279936.
    [7] MULGAONKAR S, KAUFMAN DB. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients[J]. Clin Transplant, 2014, 28(11): 1209-1224. DOI: 10.1111/ctr.12453.
    [8] NAGAO RJ, MARCU R, SHIN YJ, et al. Cyclosporine induces fenestra-associated injury in human renal microvessels in vitro[J]. ACS Biomater Sci Eng, 2022, 8(1): 196-207. DOI: 10.1021/acsbiomaterials.1c00986.
    [9] WU Q, WANG X, NEPOVIMOVA E, et al. Mechanism of cyclosporine A nephrotoxicity: oxidative stress, autophagy, and signaling[J]. Food Chem Toxicol, 2018, 118: 889-907. DOI: 10.1016/j.fct.2018.06.054.
    [10] VERPOOTEN GA, COOLS FJ, VAN DER PLANKEN MG, et al. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients[J]. Nephrol Dial Transplant, 1996, 11(2): 347-351. DOI: 10.1093/oxfordjournals.ndt.a027265.
    [11] RENNER B, KLAWITTER J, GOLDBERG R, et al. Cyclosporine induces endothelial cell release of complement-activating microparticles[J]. J Am Soc Nephrol, 2013, 24(11): 1849-1862. DOI: 10.1681/ASN.2012111064.
    [12] NAVA F, CAPPELLI G, MORI G, et al. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation[J]. Transplant Proc, 2014, 46(7): 2263-2268. DOI: 10.1016/j.transproceed.2014.07.062.
    [13] KEIR LS, FIRTH R, APONIK L, et al. VEGF regulates local inhibitory complement proteins in the eye and kidney[J]. J Clin Invest, 2017, 127(1): 199-214. DOI: 10.1172/JCI86418.
    [14] AL-NOURI ZL, REESE JA, TERRELL DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports[J]. Blood, 2015, 125(4): 616-618. DOI: 10.1182/blood-2014-11-611335.
    [15] BAID-AGRAWAL S, FARRIS AB 3RD, PASCUAL M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy[J]. Kidney Int, 2011, 80(8): 879-885. DOI: 10.1038/ki.2011.194.
    [16] RANE S, NADA R, MINZ M, et al. Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients[J]. Transplant Proc, 2012, 44(3): 713-716. DOI: 10.1016/j.transproceed.2011.11.052.
    [17] JAVA A, EDWARDS A, ROSSI A, et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature[J]. Transpl Int, 2015, 28(9): 1121-1125. DOI: 10.1111/tri.12582.
    [18] MITSUIKI N, TAMANUKI K, SEI K, et al. Severe neonatal CMV infection complicated with thrombotic microangiopathy successfully treated with ganciclovir[J]. J Infect Chemother, 2017, 23(2): 107-110. DOI: 10.1016/j.jiac.2016.08.007.
    [19] THOREAU B, VON TOKARSKI F, BAUVOIS A, et al. Infection in patients with suspected thrombotic microangiopathy based on clinical presentation[J]. Clin J Am Soc Nephrol, 2021, 16(9): 1355-1364. DOI: 10.2215/CJN.17511120.
    [20] ARDALAN MR, SHOJA MM, TUBBS RS, et al. Parvovirus B19 microepidemic in renal transplant recipients with thrombotic microangiopathy and allograft vasculitis[J]. Exp Clin Transplant, 2008, 6(2): 137-143.
    [21] STEFFEN CJ, KOCH N, ECKARDT KU, et al. Hemophagocytic lymphohistiocytosis and thrombotic microangiopathy after parvovirus B19 infection and renal transplantation: a case report[J]. BMC Nephrol, 2021, 22(1): 337. DOI: 10.1186/s12882-021-02538-0.
    [22] WU K, BUDDE K, SCHMIDT D, et al. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy[J]. Clin Transplant, 2016, 30(2): 105-117. DOI: 10.1111/ctr.12645.
    [23] FARKASH EA, COLVIN RB. Diagnostic challenges in chronic antibody-mediated rejection[J]. Nat Rev Nephrol, 2012, 8(5): 255-257. DOI: 10.1038/nrneph.2012.61.
    [24] 中华医学会器官移植学分会. 肾移植排斥反应临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(5): 505-512. DOI: 10.3969/j.issn.1674-7445.2019.05.008.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for the diagnosis and treatment on rejection of renal transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(5): 505-512. DOI: 10.3969/j.issn.1674-7445.2019.05.008.
    [25] LOUPY A, HAAS M, ROUFOSSE C, et al. The Banff 2019 kidney meeting report (Ⅰ): updates on and clarification of criteria for T cell- and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(9): 2318-2331. DOI: 10.1111/ajt.15898.
    [26] BLASCO M, GUILLÉN-OLMOS E, DIAZ-RICART M, et al. Complement mediated endothelial damage in thrombotic microangiopathies[J]. Front Med (Lausanne), 2022, 9: 811504. DOI: 10.3389/fmed.2022.811504.
    [27] NORIS M, REMUZZI G. Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?[J]. Kidney Int, 2019, 96(1): 13-15. DOI: 10.1016/j.kint.2019.02.038.
    [28] TAYLOR CM, MACHIN S, WIGMORE SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom[J]. Br J Haematol, 2010, 148(1): 37-47. DOI: 10.1111/j.1365-2141.2009.07916.x.
    [29] LEVI C, FRÉMEAUX-BACCHI V, ZUBER J, et al. Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence[J]. Transplantation, 2017, 101(12): 2924-2930. DOI: 10.1097/TP.0000000000001909.
    [30] PRÉVEL R, DELMAS Y, GUILLOTIN V, et al. Complement blockade is a promising therapeutic approach in a subset of critically ill adult patients with complement-mediated hemolytic uremic syndromes[J]. J Clin Med, 2022, 11(3): 790. DOI: 10.3390/jcm11030790.
    [31] PALOMO M, BLASCO M, MOLINA P, et al. Complement activation and thrombotic microangiopathies[J]. Clin J Am Soc Nephrol, 2019, 14(12): 1719-1732. DOI: 10.2215/CJN.05830519.
    [32] BLASCO M, GUILLÉN E, QUINTANA LF, et al. Thrombotic microangiopathies assessment: mind the complement[J]. Clin Kidney J, 2020, 14(4): 1055-1066. DOI: 10.1093/ckj/sfaa195.
    [33] GARG N, RENNKE HG, PAVLAKIS M, et al. De novo thrombotic microangiopathy after kidney transplantation[J]. Transplant Rev (Orlando), 2018, 32(1): 58-68. DOI: 10.1016/j.trre.2017.10.001.
    [34] ZHENG L, ZHANG D, CAO W, et al. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy[J]. Blood, 2019, 134(13): 1095-1105. DOI: 10.1182/blood.2019001040.
    [35] BUDDE K, PRASHAR R, HALLER H, et al. Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial[J]. J Am Soc Nephrol, 2021, 32(12): 3252-3264. DOI: 10.1681/ASN.2021050628.
    [36] ASHMAN N, CHAPAGAIN A, DOBBIE H, et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy[J]. Am J Transplant, 2009, 9(2): 424-427. DOI: 10.1111/j.1600-6143.2008.02482.x.
    [37] JORDAN SC, AMMERMAN N, CHOI J, et al. The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection[J]. Am J Transplant, 2020, 20 (Suppl 4): 42-56. DOI: 10.1111/ajt.15913.
    [38] SCHWOTZER N, PAGANETTI G, BARCHI M, et al. Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation[J]. Xenotransplantation, 2020, 27(4): e12630. DOI: 10.1111/xen.12630.
    [39] MEEHAN SM, KREMER J, ALI FN, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies[J]. Clin J Am Soc Nephrol, 2011, 6(2): 395-403. DOI: 10.2215/CJN.05870710.
    [40] ÖZLÜ SG, GÜLHAN B, AYDOĞ Ö, et al. Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?[J]. Turk J Pediatr, 2021, 63(6): 986-993. DOI: 10.24953/turkjped.2021.06.006.
    [41] MITTAL A, DIJOO M, AGGARWAL S, et al. Rituximab to abbreviate plasma exchange in anti-CFH (complement factor H) antibody mediated atypical HUS[J]. Iran J Kidney Dis, 2019, 13(2): 134-138.
    [42] AIGNER C, BÖHMIG GA, ESKANDARY F, et al. Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients[J]. Eur J Intern Med, 2020, 73: 51-58. DOI: 10.1016/j.ejim.2019.11.007.
    [43] ZUBER J, LE QUINTREC M, SBERRO-SOUSSAN R, et al. New insights into postrenal transplant hemolytic uremic syndrome[J]. Nat Rev Nephrol, 2011, 7(1): 23-35. DOI: 10.1038/nrneph.2010.155.
    [44] GONZALEZ SUAREZ ML, THONGPRAYOON C, MAO MA, et al. Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis[J]. J Clin Med, 2019, 8(7): 919. DOI: 10.3390/jcm8070919.
    [45] LOIRAT C, FAKHOURI F, ARICETA G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children[J]. Pediatr Nephrol, 2016, 31(1): 15-39. DOI: 10.1007/s00467-015-3076-8.
    [46] ÖZÇAKAR ZB, OZALTIN F, GÜLHAN B, et al. Transplantation in pediatric aHUS within the era of eculizumab therapy[J]. Pediatr Transplant, 2021, 25(3): e13914. DOI: 10.1111/petr.13914.
    [47] SELLIER-LECLERC AL, FREMEAUX-BACCHI V, DRAGON-DUREY MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome[J]. J Am Soc Nephrol, 2007, 18(8): 2392-2400. DOI: 10.1681/ASN.2006080811.
    [48] JALANKO H, PELTONEN S, KOSKINEN A, et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H[J]. Am J Transplant, 2008, 8(1): 216-221. DOI: 10.1111/j.1600-6143.2007.02029.x.
    [49] KIM S, PARK E, MIN SI, et al. Kidney transplantation in patients with atypical hemolytic uremic syndrome due to complement factor H deficiency: impact of liver transplantation[J]. J Korean Med Sci, 2018, 33(1): e4. DOI: 10.3346/jkms.2018.33.e4.
    [50] COPPO R, BONAUDO R, PERUZZI RL, et al. Liver transplantation for aHUS: still needed in the eculizumab era?[J]. Pediatr Nephrol, 2016, 31(5): 759-768. DOI: 10.1007/s00467-015-3278-0.
  • 加载中
图(1)
计量
  • 文章访问数:  39
  • HTML全文浏览量:  2
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-09-28
  • 网络出版日期:  2023-01-17
  • 刊出日期:  2023-01-15

目录

    /

    返回文章
    返回